Rifaximin as a Modulator of Microbial Translocation and Immune Activation

NCT01466595 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

NETWORK

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Rifaximin

Sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Collaborators

[object Object]